HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata (IL-2)

HCW Biologics

Status and phase

Enrolling

Phase 1

Conditions

Alopecia Areata(AA)

Treatments

Drug: HCW9302, an IL-2 fusion protein

Study type

Interventional

Funder types

Industry

Identifiers

NCT07049328

HCWALO101

Details and patient eligibility

About

This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)

Full description

The study involves dose escalation to determine the toxicity profile of HCW9302 and to designate a dose level for the Phase 2 expansion phase (RP2D).

Up to five HCW9302 dose levels will be evaluated. A step-down dose level (level -1) will be provided in the event that unacceptable toxicity is encountered at the planned initial dose level. In the first stage of the study, HCW9302 will be administered subcutaneously as a single dose. Depending on the results of the single ascending dose stage, a multidose study of HCW9302 administered subcutaneously every 28 days for 4 consecutive treatments will be considered.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult women who are 18 to 70 years of age, or adult males who are 18 to 60 years of age at the time of informed consent.
Clinical diagnosis of Alopecia Areata (AA) (including ophiasis, totalis or universalis forms) at Screening.
Negative serum pregnancy test within 14 days of treatment start if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized).
Female subjects of childbearing potential must adhere to using a highly effective medically accepted method of birth control (defined as those with failure less than 1%; see Appendix 2) prior to screening and agree to continue its use for at least 28 days after the last dose of HCW9302 or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use a barrier method of birth control and agree to continue its use for at least 28 days after the last dose of HCW9302.
Laboratory tests performed within 28 days of treatment start:
1. Absolute neutrophil count (AGC/ANC) ≥ 1,500/μL (≥1.5 × 109/L)
2. Platelets ≥ 100,000/μL (≥ 100 × 109/L)
3. Hemoglobin ≥ 10 g/dL (>100g/L)
4. Calculated glomerular filtration rate (GFR)* >40 mL/min OR serum creatinine ≤ 1.5 × ULN
5. Total bilirubin ≤ 2.0 × ULN or ≤ 3.0 × ULN for subjects with Gilbert's syndrome
6. AST, ALT, ALP ≤ 2.0 × ULN
Able and willing to comply with requested study visits and procedures.
Able and willing to provide written informed consent and HIPAA authorization

Exclusion criteria

Men and women (of reproductive potential) unwilling to use birth control and women who are pregnant or breastfeeding
Patient has primarily "diffuse" type AA (characterized by diffuse hair shedding)
Presence of another form of alopecia
Prior use of any of the following treatments: a. Aldesleukin b. Investigational IL-2 analog
Concurrent use of oral or topical treatments targeting hair growth or hair restoration (including but not limited to finasteride, dutasteride, topical minoxidil or oral minoxidil) if discontinuation or dosage change is planned during the study period.
Prior use of phototherapy and any systemic immunosuppressant (systemic steroids, cyclosporin, methotrexate or any other immunosuppressive therapy) or immunomodulating biologic therapy (including but not limited to dupilumab, tralokinumab, lebrikizumab, nemolizumab, rocatinlimab, or daxdilimab, whether marketed or investigational) within 3 months prior to Screening.
Prior use of any B-cell depleting agents, whether marketed or investigational, including but not limited to rituximab, ocrelizumab, ofatumumab, or belimumab, within 6 months prior to Screening.
Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study.
History of diabetes mellitus, regardless of whether it is controlled or not.
History of myocardial infarction, congestive heart failure, uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension, or uncontrolled diabetes within 6 months prior to Screening.
Significant organ dysfunction that is unstable or inadequately treated within 6 months prior to Screening.
History of cancer or lymphoproliferative disease, except for the following: adequately treated basal cell or squamous cell skin cancer without current evidence of disease.
Currently receiving any chronic systemic (oral or intravenous) anti-infective therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).
Active tuberculosis (TB) (based on TB blood test or a TB skin test) or a history of inadequately treated TB.
Herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months prior to Screening. Subjects with a history of frequent outbreaks of Herpes Simplex Virus (defined as 4 or more outbreaks a year).
Major surgery within 3 months prior to Screening visit or has a major surgery planned during the study.
Active systemic infection requiring parenteral antibiotic/antiviral therapy. All prior infections must have resolved following optimal therapy.
Prior organ allograft or allogeneic transplantation.
Positive based on serological screening for human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening.
Any ongoing toxicity from prior therapies that, in the judgment of the Investigator, may interfere with study treatment. All toxicities attributed to prior therapy must resolve to grade 1 or baseline before administration of the study treatment.
Psychiatric illness/social situations that would limit compliance with study requirements.
Other skin conditions that would interfere with study assessments of AA.
Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this study.